Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs Nuwellis Inc (NUWE) Price & Performance

Barclays PLCTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs Nuwellis Inc — how do they compare? Barclays PLC trades at $27.87 (market cap $94.10B), while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: Barclays PLC is far larger — about 180006.1× Nuwellis Inc's market cap, and Barclays PLC pays a 2.18% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

BCSNUWE
Market Cap
$94.10B$522.76K
Sector
FinancialsTechnology
52-Week High
$28.56$220.50
52-Week Low
$19.36$1.42
Dividend Yield
2.18%
Enterprise Value
-$1.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.

The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.

Nuwellis Inc

NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.

The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE